When I first chatted about VirnetX (VHC) on CNBC in July 2011, when the stock was around $23 and on its way up to $40, I said this would become the next big battleground stock.
Indeed it was. Investors piled in amid the hope and hype that VirnetX, a 2007 reverse merger, would file and win a bunch of patent suits against the big-tech guns such as Microsoft (MSFT), Cisco (CSCO) and Apple (AAPL). It actually won a suit in 2010 against Microsoft.
As I wrote in 2012:
"The bulls believe VirnetX is setting itself up to be the next Qualcomm [(QCOM)] with patents, acquired from SAIC, which control secure communications between 4G mobile devices. An analyst at Cowen is in print saying he believes the patents could be valued more than $3 billion.
"Bears, meanwhile, believe that based on almost any other patent case, in any settlement VirnetX is likely to get a fraction of what the bulls expect -- assuming it wins any or all of its suits."
As it turns out, VirnetX had some impressive victories. But, as the bears predicted, the company snared a fraction of what the bulls expected. Apple was supposed to be the big win, and a jury awarded the company $368 million. But, earlier this week, an appeals court threw out that award -- or, as VirnetX put it, "remanded the damages award . . . for further proceedings."
In other words, it's back to the drawing boards.
Reality: Betting on patent fights is like betting on biotech, and the verdict of an appeals court is like getting the results of a phase III trial. For almost everybody involved, including the supposedly smart people, it's a crapshoot.
Want more from Herb Greenberg? Sign up for Reality Check, his institutional research product, and get the watch list of all the companies on his radar with detailed analysis.